A Randomized Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab+Docetaxel to Dostarlimab+Docetaxel to Docetaxel Alone in Participants with Advanced Nonsmall Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (Costar Lung)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Participant has histologically or cytologically proven advanced or metastatic NSCLC, including squamous or nonsquamous cell carcinoma. 2) Participant has received no more than 2 prior lines of therapy, which must include a platinum-based chemotherapy (eg, cisplatin, carboplatin) and an anti-PD-(L)1 antibody. 3) Participant has measurable disease, that is, presenting with at least 1 measurable lesion per RECIST v1.1 as determined by the local site Investigator/radiology assessment.

You may not be eligible for this study if the following are true:

  • 1) Participant has been previously treated with an anti-PD-(L)1 or anti-PD-L2 agent that resulted in permanent discontinuation due to an AE. 2) Participant has been previously treated with an anti-TIM-3 or anti-CTLA-4 agent or docetaxel. 3) Participant has a documented sensitizing EGFR, ALK, or ROS-1 mutation.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.